Baskin C R, Couto C G, Wittum T E
Department of Veterinary Clinical Sciences and Comprehensive Cancer Center, College of Veterinary Medicine, The Ohio State University, Columbus 43210-1089, USA.
J Am Anim Hosp Assoc. 2000 Sep-Oct;36(5):404-9. doi: 10.5326/15473317-36-5-404.
Records of 145 dogs diagnosed with lymphoma were reviewed to evaluate for factors influencing duration of remission and survival. Dogs with histories of certain chronic inflammatory diseases were 3.23 times more likely to relapse (relative risk, 3.23) than the overall population. Dogs with World Health Organization (WHO) stage IV lymphoma or those treated with a protocol containing cyclophosphamide, doxorubicin, vincristine, prednisone, and sulfatrimethoprim (CHOP) had lower relative risks of relapse (0.32 and 0.085, respectively). Progressive disease after induction, gastrointestinal toxicity from induction, and clinical signs (i.e., substage b lymphoma) were associated with higher relative risks of death (3.5, 2.64, and 2.02, respectively).
回顾了145只被诊断为淋巴瘤的犬的记录，以评估影响缓解期和生存期的因素。有某些慢性炎症性疾病病史的犬复发的可能性是总体犬群的3.23倍（相对风险为3.23）。患有世界卫生组织（WHO）IV期淋巴瘤的犬或接受包含环磷酰胺、阿霉素、长春新碱、泼尼松和磺胺甲恶唑（CHOP）方案治疗的犬复发的相对风险较低（分别为0.32和0.085）。诱导治疗后病情进展、诱导治疗引起的胃肠道毒性以及临床症状（即b期淋巴瘤）与较高的死亡相对风险相关（分别为3.5、2.64和2.02）。
Zotero 插件